Risk assessment of venous thrombosis in families with known hereditary thrombophilia: The MARseilles-NImes prediction model

Journal of Thrombosis and Haemostasis

Volumn 12, Issue 2, 2014, Pages 138-146

  Cohen, W ^a,b   Castelli, C ^c   Suchon, P ^a,b   Bouvet, S ^c   Aillaud, M F ^a,b   Brunet, D ^b   Barthet, M C ^b   Alessi, M C ^a,b   Tregouet D A ^d,e   Morange, P E ^a,b  

^a AIX MARSEILLE UNIVERSITY   (France)

^b TIMONE HOSPITAL   (France)

^c NÎMES UNIVERSITY HOSPITAL   (France)

^d INSERM   (France)

^e SORBONNE UNIVERSITÉ   (France)

Author keywords

Evidence based medicine; Risk assessment; Single nucleotide, polymorphism; Thrombophilia; Venous thrombosis

Indexed keywords

ANTITHROMBIN; BLOOD CLOTTING FACTOR 5 LEIDEN; PROTEIN C; PROTEIN S; VON WILLEBRAND FACTOR;

ADOLESCENT; ADULT; AGED; ANTITHROMBIN DEFICIENCY; ARTICLE; BLOOD CLOTTING FACTOR DEFICIENCY; BLOOD GROUP ABO SYSTEM; CHILD; FAMILIAL DISEASE; FAMILY HISTORY; FEMALE; FRANCE; HUMAN; IMMOBILIZATION; INFANT; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NEOPLASM; NEWBORN; ORAL CONTRACEPTIVE USE; PATIENT REFERRAL; PREDICTION; PREGNANCY; PRESCHOOL CHILD; PRIORITY JOURNAL; PROTEIN C DEFICIENCY; PROTEIN S DEFICIENCY; PUERPERIUM; RISK ASSESSMENT; SCHOOL CHILD; SCORING SYSTEM; SEX DIFFERENCE; SURGICAL INJURY; THROMBOPHILIA; VEIN THROMBOSIS; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; INFANT; INFANT, NEWBORN; MALE; MIDDLE AGED; MODELS, THEORETICAL; RISK ASSESSMENT; THROMBOPHILIA; VENOUS THROMBOSIS; YOUNG ADULT;

EID: 84893635208     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/jth.12461     Document Type: Article

References (26)

1. Rosendaal FR, Reitsma PH. Genetics of venous thrombosis. J Thromb Haemost 2009; 7(Suppl. 1): 301-4.
2. Middeldorp S, van Hylckama Vlieg A. Does thrombophilia testing help in the clinical management of patients? Br J Haematol 2008; 143: 321-35.
3. Moll S. Who should be tested for thrombophilia? Genet Med 2011; 13: 19-20.
4. Baglin T, Gray E, Greaves M, Hunt BJ, Keeling D, Machin S, Mackie I, Makris M, Nokes T, Perry D, Tait RC, Walker I, Watson H; British Committee for Standards in Haematology. Clinical guidelines for testing for heritable thrombophilia. Br J Haematol 2010; 149: 209-20.
5. Lensen RP, Bertina RM, de Ronde H, Vandenbroucke JP, Rosendaal FR. Venous thrombotic risk in family members of unselected individuals with factor V Leiden. Thromb Haemost 2000; 83: 817-21.
6. Cohen W, Castelli C, Alessi MC, Aillaud MF, Bouvet S, Saut N, Brunet D, Barthet MC, Tregouet DA, Lavigne G, Morange PE. ABO blood group and von Willebrand factor levels partially explained the incomplete penetrance of congenital thrombophilia. Arterioscler Thromb Vasc Biol 2012; 32: 2021-8.
7. Pernod G, Biron-Andreani C, Morange PE, Boehlen F, Constans J, Couturaud F, Drouet L, Jude B, Lecompte T, Le Gal G, Trillot N, Wahl D; French Group on Haemostasis and Thrombosis; French Society of Vascular Medicine. Recommendations on testing for thrombophilia in venous thromboembolic disease: a French consensus guideline. J Mal Vasc 2009; 34: 156-203.
8. Germain M, Saut N, Greliche N, Dina C, Lambert JC, Perret C, Cohen W, Oudot-Mellakh T, Antoni G, Alessi MC, Zelenika D, Cambien F, Tiret L, Bertrand M, Dupuy AM, Letenneur L, Lathrop M, Emmerich J, Amouyel P, Trégouët DA, et al. Genetics of venous thrombosis: insights from a new genome wide association study. PLoS ONE 2011; 6: e25581.
9. Morange PE, Tregouet DA. Lessons from genome-wide association studies in venous thrombosis. J Thromb Haemost 2011; 9(Suppl. 1): 258-64.
10. DeLong ER, DeLong DM, Clarke-Pearson DL. Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics 1988; 44: 837-45.
11. Harrell FE Jr, Lee KL, Mark DB. Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med 1996; 15: 361-87.
12. Bezemer ID, van der Meer FJ, Eikenboom JC, Rosendaal FR, Doggen CJ. The value of family history as a risk indicator for venous thrombosis. Arch Intern Med 2009; 169: 610-15.
13. Zoller B, Li X, Sundquist J, Sundquist K. Age- and gender-specific familial risks for venous thromboembolism: a nationwide epidemiological study based on hospitalizations in Sweden. Circulation 2011; 124: 1012-20.
14. Prandoni P, Prins MH, Ghirarduzzi A, Pengo V, Sartori MT, Ugolotti MC, Bracco A, Veropalumbo MR, Noventa F, Lensing AW. Family history of venous thrombosis or sudden death as a risk factor for venous thromboembolism. Thromb Haemost 2012; 107: 1191-2.
15. Wilson BJ, Qureshi N, Santaguida P, Little J, Carroll JC, Allanson J, Raina P. Systematic review: family history in risk assessment for common diseases. Ann Intern Med 2009; 151: 878-85.
16. Ridker PM, Glynn RJ, Miletich JP, Goldhaber SZ, Stampfer MJ, Hennekens CH. Age-specific incidence rates of venous thromboembolism among heterozygous carriers of factor V Leiden mutation. Ann Intern Med 1997; 126: 528-31.
17. Heit JA, Silverstein MD, Mohr DN, Petterson TM, Lohse CM, O'Fallon WM, Melton LJ 3rd. The epidemiology of venous thromboembolism in the community. Thromb Haemost 2001; 86: 452-63.
18. Couturaud F, Kearon C, Leroyer C, Mercier B, Abgrall JF, Le Gal G, Lacut K, Oger E, Bressollette L, Ferec C, Lamure M, Mottier D; Groupe d'Etude de la Thrombose de Bretagne Occidentale (G.E.T.B.O.). Incidence of venous thromboembolism in first-degree relatives of patients with venous thromboembolism who have factor V Leiden. Thromb Haemost 2006; 96: 744-9.
19. Koster T, Blann AD, Briet E, Vandenbroucke JP, Rosendaal FR. Role of clotting factor VIII in effect of von Willebrand factor on occurrence of deep-vein thrombosis. Lancet 1995; 345: 152-5.
20. Smith NL, Rice KM, Bovill EG, Cushman M, Bis JC, McKnight B, Lumley T, Glazer NL, van Hylckama Vlieg A, Tang W, Dehghan A, Strachan DP, O'Donnell CJ, Rotter JI, Heckbert SR, Psaty BM, Rosendaal FR. Genetic variation associated with plasma von Willebrand factor levels and the risk of incident venous thrombosis. Blood 2011; 117: 6007-11.
21. O'Donnell J, Boulton FE, Manning RA, Laffan MA. Amount of H antigen expressed on circulating von Willebrand factor is modified by ABO blood group genotype and is a major determinant of plasma von Willebrand factor antigen levels. Arterioscler Thromb Vasc Biol 2002; 22: 335-41.
22. Morange PE, Simon C, Alessi MC, Luc G, Arveiler D, Ferrieres J, Amouyel P, Evans A, Ducimetiere P, Juhan-Vague I; PRIME Study Group. Endothelial cell markers and the risk of coronary heart disease: the Prospective Epidemiological Study of Myocardial Infarction (PRIME) study. Circulation 2004; 109: 1343-8.
23. Reitsma PH, Versteeg HH, Middeldorp S. Mechanistic view of risk factors for venous thromboembolism. Arterioscler Thromb Vasc Biol 2012; 32: 563-8.
24. Hippisley-Cox J, Coupland C. Development and validation of risk prediction algorithm (QThrombosis) to estimate future risk of venous thromboembolism: prospective cohort study. BMJ 2011; 343: d4656.
25. de Haan HG, Bezemer ID, Doggen CJ, Le Cessie S, Reitsma PH, Arellano AR, Tong CH, Devlin JJ, Bare LA, Rosendaal FR, Vossen CY. Multiple SNP testing improves risk prediction of first venous thrombosis. Blood 2012; 120: 656-63.
26. Eichinger S, Heinze G, Jandeck LM, Kyrle PA. Risk assessment of recurrence in patients with unprovoked deep vein thrombosis or pulmonary embolism: the Vienna prediction model. Circulation 2010; 121: 1630-6.